Medicare Pays Tens of Thousands After a Heart Attack, Yet Prevention Could Cost About $100

Guidelines are finally catching up with the evidence behind coronary artery calcium scans

Medical science is advancing quickly, but healthcare delivery often lags behind. One clear example is coronary artery disease, the leading cause of death and disability in the United States. More than 800,000 Americans have a heart attack each year, and most of those events can be prevented. A coronary artery calcium score, or CAC, is a quick 10-minute scan that can show how much coronary atherosclerosis is present years before it leads to a heart attack. It costs about $100 and uses far less radiation than a standard chest CT.

After more than three decades of evidence, the American College of Cardiology and the American Heart Association placed CAC at the center of their national prevention guidelines in March 2026. The scan, which detects calcified plaque in the arteries, is recommended for adults at borderline or intermediate risk when the decision to begin preventive treatment, such as statins, is still uncertain.

For years, doctors have depended on risk calculators based on age, sex, cholesterol, diabetes, blood pressure, and smoking to estimate the likelihood of a heart attack. Those tools measure probability, not actual disease. A CAC scan, by contrast, shows whether coronary atherosclerosis is already there. That matters because someone with only mildly abnormal cholesterol may already have extensive plaque, while another person with high cholesterol may have none. A score of zero can lower a patient’s risk category and help avoid unnecessary medication, while a score above 100 points to patients who may benefit from drug therapy and more intensive lifestyle changes.

Take Rob*, a 52-year-old patient seen recently. He exercises, eats well, and has borderline high cholesterol. He also has a family history of heart disease, but no other known cardiac risk factors. Based on the standard risk calculator, he falls into a low-risk group and would prefer to avoid treatment.

His CAC score tells a different story. It is 220, which indicates a significant burden of plaque for a man his age. Because genetics account for about half of cardiovascular risk and are not included in common risk calculators, the scan showed that medication gives Rob his best chance of avoiding a future heart attack.

Even with years of evidence showing that CAC is better than conventional risk factors at predicting heart attacks, it remained only a minor part of national guidelines for decades. So why the delay?

One reason is structural. Clinical decision tools were designed to adjust average population risk factors, not to incorporate personalized imaging. Guideline panels understandably move slowly, and prevention is harder to standardize than treating established disease. As a result, cardiologists and primary care doctors, limited by what insurers will pay for, often offer the test mainly to patients who can cover it themselves.

With the updated ACC/AHA guidance, heart attack prevention is now centered on a simple idea: when possible, measure the disease directly.

Artificial intelligence is also reshaping the economics of prevention. Millions of Americans already receive chest CT scans for other reasons, but the cardiovascular clues visible on those images are often overlooked. AI can detect coronary and vascular calcification opportunistically, standardize the reports, and identify patients who should get a formal preventive workup. That is especially valuable for people least able to pay cash for elective testing.

AI-CAC is now also being used to assess soft plaque, an important precursor to the hard plaque seen on traditional calcium scores. Used responsibly, AI-based CAC analysis could help move heart disease prevention to the level of population health.

Heart attacks are largely preventable, and for more than a generation we have had the tools to find the disease early and treat it in time. What has been missing is a payment system that is willing to spend $100 to avoid a $50,000 emergency.

The CAC story is not unique. It reflects how a low-cost, low-risk, well-studied tool can remain at the margins of practice for decades because the surrounding systems — guidelines, reimbursement rules, and clinical habits — were never built to absorb it.

The evidence has been strong for years, and the guidelines have finally caught up.